Mitotech Logo
  • Our technology
  • Our Pipeline
  • Who We Are
    About Us News & Events Contact Us
  • Team
    Management Team Advisory Board

News

February 24, 2022Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit
January 26, 2022Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease
December 15, 2021Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON
May 6, 2021Mitotech's focus on opthalmology discussed in Fierce Biotech publication
March 4, 2021Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021
February 26, 2021Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease
February 1, 2021Mitotech to present at LSX Congress 2021
January 11, 2021Mitotech S.A. To Present at Biotech Showcase Digital 2021 Conference
October 23, 2020Mitotech to present in Eyecelerator's Retina Livestream organized by AAO and ASCRS
August 25, 2020Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
December 12, 2019Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 - a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease
October 29, 2018Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease
October 23, 2018Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology
July 19, 2018Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease
October 24, 2017Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action
April 26, 2017Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients
April 20, 2017Mitotech's SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication
March 21, 2017Mitotech's lead compound significantly increased lifespan of rapidly aging mice
February 10, 2017Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article
February 7, 2017Mitotech will attend the Biotech and Money conference in London, Feb 7-8, 2017
January 20, 2017Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations
September 9, 2016Mitotech S.A. is granted a patent in anti-aging
July 27, 2016Mitotech S.A. announces its Ophthalmic Scientific Advisory Board
March 20, 2016Oxidative stress and dry eye in Review of Ophthalmology
March 1, 2016Mitotech S.A. to present at ARVO 2016
February 5, 2016Mitotech CEO to present at the annual BIO CEO and Investor Conference 2016
January 25, 2016Mitotech S.A. to initiate its first clinical study of a systemic formulation of SkQ1
January 10, 2016Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
December 27, 2015Results of Mitotech's Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal
October 16, 2015Mitotech S.A. to present at the 2015 Sofinnova Japan Biopharma Partnering Conference
May 3, 2015Mitotech's posters at ARVO 2015 in Denver, May 3-7
April 23, 2015Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome
April 21, 2014Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment
May 14, 2013Mitotech completes series of uveitis studies
December 9, 2012Mitotech's posters at ARVO 2015 in Denver, May 3-7
January 17, 2012Mitotech initiated pre-clinical program for SkQ1 compound in the U.S.

© 2021 Mitotech, SA - All Rights Reserved - Privacy Policy